LNC
OTLK icon

Lincoln National Corp’s Outlook Therapeutics OTLK Stock Holding History

Lincoln National Corp’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,165
Closed -$24.9K – 1228
2023
Q4 		$24.9K Sell
3,165
-12,850
-80% -$109K ﹤0.01% 1094
2023
Q3 		$70.8K Hold
16,015
– – ﹤0.01% 1004
2023
Q2 		$557K Buy
16,015
+6,300
+65% +$172K 0.01% 562
2023
Q1 		$212K Hold
9,715
– – ﹤0.01% 910
2022
Q4 		$210K Buy
9,715
+2,050
+27% +$44.6K ﹤0.01% 857
2022
Q3 		$187K Hold
7,665
– – ﹤0.01% 820
2022
Q2 		$156K Buy
7,665
+2,500
+48% +$71.9K ﹤0.01% 819
2022
Q1 		$184K Hold
5,165
– – ﹤0.01% 872
2021
Q4 		$140K Sell
5,165
-7,500
-59% -$268K ﹤0.01% 862
2021
Q3 		$550K Hold
12,665
– – 0.01% 474
2021
Q2 		$631K Buy
+12,665
New +$588K 0.01% 427

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Lincoln National Corp's OTLK Position: Q1 2024 in Review

Lincoln National Corp sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 3,165 shares — an estimated $24.9K sold.

Lincoln National Corp first reported a position in OTLK in Q2 2021 and held it in 11 quarters. The position peaked at $631K in Q2 2021. 56 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Lincoln National Corp reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Lincoln National Corp sold 3,165 Outlook Therapeutics shares in Q1 2024, an estimated $24.9K.
  • Lincoln National Corp first reported a position in Outlook Therapeutics in Q2 2021 and held it in 11 quarters.
  • Lincoln National Corp's Outlook Therapeutics position peaked at $631K in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Lincoln National Corp's 13F filing for Q1 2024, filed 2 May 2024.